Grow Pharma has announced it will launch its own range of medical cannabis flowers to improve accessibility of prescribed cannabis medicines.
Leading supplier of prescribed cannabis medicines, Grow Pharma, announced today the launch of their own brand of medical cannabis flowers for UK patients.
This will start with a mid-range THC sativa and a balanced-ratio hybrid with a third, indica flower, to follow in the coming weeks.
The UK medical cannabis market is still in its infancy, with many patients now receiving prescribed medical cannabis, since moving to regulated, safer and legally prescribed products with medical oversight of their treatment.
Many of these patients have a broad knowledge of the cannabis plant and its active ingredients and are very often used to certain cultivars (strains) that are providing the best relief for their symptoms. In order to cater for both these “experienced” patients and for the other side of the coin; the “cannabis naïve” patients, Grow Pharma aims to have the broadest possible range of cannabis medicines available for doctors and patients.
Towards that aim Grow recently launched capsules and is constantly looking into new modes of administration. Soon the company will launch medical cannabis vape (oil) pens with their partner, Columbia Care, who also introduced the capsules.
The launch of the Grow flower medicines fits this narrative. The cultivars and cannabinoid ratios will be in addition to Grow’s range of premium branded products from Aurora and Tilray, further increasing the options available for patients.
Pricing is moderate and will allow patients to use only these products or combine premium brands with Grow’s own quality brand to create the optimal symptom management for patients who have exhausted other pharmaceutical options or are suffering too many side effects from these medications.
Grow’s focus on patients also means that, as with the other brands, there is a consistent and sustainable supply of these products via their pharmacy partners, IPS Pharma.
Grow and IPS already represent world-renowned producers of medical cannabis Aurora, Tilray and Columbia Care and recently signed an agreement with ALT to bring their liquid medical cannabis products to Europe early next year.
Grow has the broadest range of cannabis medicines in the UK, with 20 flower and 25 oil medicines, including these new additions, as well as the capacity to formulate oils with bespoke ratios of THC and CBD where required. They are also the only UK supplier to stock a range of hard-shell medical cannabis capsules, manufactured locally for USA producer Columbia Care.
“Cannabis medicines are so personal to the individual patient; this is why it’s important for us to ensure doctors have a wide-range of options to choose from when treating patients,” commented GROW’s patient access lead and prominent medical cannabis advocate, Alex Fraser.
“We already have the widest range prior to the addition of the GROW Flowers, but we felt we needed to offer more options alongside the flower ranges we stock from Aurora and Tilray, to ensure that even more patients can benefit from these medicines and the fast and efficient pharmacy service IPS provide.”
With prescription numbers for cannabis medicines in the UK increasing month-on-month and more doctors entering the space, it is no surprise to see a company like Grow launching its own brand.
However, GROW CEO Pierre Van Weperen stated: “One of the things that makes us the supplier of choice for doctors prescribing cannabis medicines is that we provide a wide range from multiple leading producers. This means the doctors we support can make the best decisions for their patients and we can ensure consistency in the supply of patient’s medicines.
“We continue to see enormous benefit of supplying medicines from multiple reputable producers. The globally leading brands are all working with us and together we are all working on driving access for patients to these products. There are several hundred thousand UK patients out there who would potentially benefit from these cannabis medicines. The introduction of our GROW flowers brand will only strengthen our broad offering and these efforts”.
Grow Pharma’s parent company Grow Group recently completed an acquisition of Sanoid Isolates, a major cultivation and extraction facility located in Seville, Spain where Grow intends to breed unique cultivars and produce new medicines based on the needs of doctors and patients.
Doctors can find information on the medicines GROW supplies by contacting them directly or by signing up to the recently launched HCP Portal where they can also speak privately to other doctors in the field and find out about the latest educational events on medical cannabis for healthcare professionals.
The post Grow Pharma to launch own-brand cannabis flower appeared first on Cannabis Health News.
